The American Society of Clinical Oncology® Endorses the WIN 2016 Symposium
Posted: Wednesday, April 20, 2016
The American Society of Clinical Oncology® Endorses the WIN 2016 Symposium: Innovative Approaches to Improve Cancer Patient Outcomes, June 27-28, 2016, Paris, France
VILLEJUIF, France--(BUSINESS WIRE)--The WIN Consortium (WIN) is proud to announce that its symposium dedicated to “Innovative approaches to improve cancer patient outcomes” has been endorsed by the American Society of Clinical Oncology (ASCO®) for its exceptional scientific program. “It is the 8th consecutive year that ASCO® has endorsed this unique scientific forum, that has become a major event in Precision Cancer Medicine”, said John Mendelsohn, Director for MD Anderson Institute for Personalized Cancer Therapy and Chairman of WIN.
WIN 2016’s symposium will be of exceptional value, as it will address very challenging and controversial themes. Precision medicine, as announced by the US President Barack Obama, has become a key objective shared by the oncology community. A special forum will be dedicated to discuss how to expedite precision cancer medicine with the outstanding participation of Bruce E. Johnson (ASCO® 2017 president elect), Richard L. Schilsky (ASCO®’s Chief Medical Officer and Chairman of WIN Scientific Advisory Board), Razelle Kurzrock (UCSD), William Sellers (Novartis), John Mendelsohn and many others.
The WIN symposium has increasingly become the forum where academia and industry share in a very candid way the latest innovations in cancer personalized medicine. But since there is no innovation without patients, this year, WIN2016 will present the opportunity for patient advocates to voice their opinions, in particular, Francesco de Lorenzo, the President of the European Cancer Patient Coalition (ECPC).
The greatest experts in the field of personalized and systems biology medicine in oncology will contribute to the program under the chairmanship of Dr. Josep Tabernero (Vall d’Hebron, Spain): Alberto Bardelli, Andrea Califano, Stephen Friend, Leroy Hood, Gordon B. Mills, and many others from academia, industry and cancer research organizations. They will present the latest innovations aiming at improving the survival and quality of life of cancer patients in the following sessions:
New tools for early diagnosis, selecting therapies and monitoring
Innovative clinical trials to substantially improve outcome
Relevant models and critical preclinical data before moving to the clinic
Translation of big data into clinical opportunities
The WIN 2016 symposium is the only event of its kind that enables all stakeholders of cancer care, from academia to industry, to present their latest advances.
For more information, take a look at www.winsymposium.org
This program is endorsed by ASCO®. ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. used with permission. This is not an ASCO® sponsored event.
Chief Operating Officer
Diversity of Stakeholders - WIN Members
Studies with a global population
Sharing information to promote use of personalized, targeted cancer therapy: WIN Symposia
WIN was created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN aims to initiate research projects each year in a global consortium guided by an independent scientific advisory board.
WIN now includes 43 institutional members. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations—from North and South America, Europe, Asia, and the Middle East.
Our goal is to significantly improve outcomes for patients around the globe. We aim to increase the number of patients worldwide that have access to innovative, global clinical trials in the area of genomic-based cancer therapeutics. Global diversity and inclusion of all stakeholders is WIN’s most important and differentiating asset.
Our members include leading academic, pharmaceutical, life science, not-for-profit, health IT, and healthpayer organizations.
WIN's first trial, WINTHER, is currently being carried out through a collaboration between six academic centers in five countries, with key support from Europe (EUFP7), Fondation ARC, Pfizer and other pharma companies.